Ocugen Biotherapeutics
Mar 22, 2018
Business Cocktail
Merck and Eisai has entered into an Oncology Pact worth Up to USD 5.76 Billion Two major pharmaceutical companies (Merck & Eisai) has entered into a USD 5.76 Billion pact to develop and commercialize Lenvima (lenvatinib mesylate) both as a monotherapy and an in-combination therapy for treating multiple types of ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
